A compound for use in the treatment of cancer selected from the group consisting of breast cancer, prostate cancer, ovarian cancer, skin cancer, brain cancer, bladder cancer, cervical cancer, liver cancer, lung cancer, leukemia, lymphoma, neuroblastoma and bone cancer, the compound having the formula: ** Formula ** in which R1 is a heteroaryl ring having from 5 to 6 ring members and from 1 to 4 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with 1-4 groups each independently selected from R1a； Each R1a is independently selected from the group consisting of hydrogen, C1-6alkyl, halogen, halo- C1-6alkyl, C1-6alkoxy, haloalkoxyC1-6, -CN, N-oxide, C3-8cycloalkyl and C3- heterocycloalkyl 8； ring J is selected from the group consisting of a cycloalkyl ring, a heterocycloalkyl ring, an aryl ring and a heteroaryl ring, in which the heterocycloalkyl and heteroaryl rings have 5 to 6 ring members and 1 to 4 heteroatoms each one independently selected from the group consisting of N, O, and S； each R 2 is independently selected from the group consisting of hydrogen, C 1-6 alkyl, halogen, C 1-6 haloalkyl, C 1-6 alkoxy, C 1-6 haloalkoxy, C 1-6 alkyl-C 1-6 alkoxy, -CN, -OH, -NR2aR2b, -C (O) R2a, -C (O) OR2a, -C (O) NR2aR2b, - SR2a, -S (O) R2a, -S (O) 2R2a, C3-8 cycloalkyl and C3-8 heterocycloalkyl , in which the heterocycloalkyl groups are optionally substituted with 1-4 R2c groups； alternatively, two R2 groups attached to the same carbon combine to form an oxo (= O) group； alternatively, two R2 groups combine to form a heterocycloalkyl ring having 5 to 6 ring members and 1 to 3 heteroatoms each independently selected from the group consisting of N, O, and S, in which the heterocycloalkyl ring is optionally substituted with 1 to 3 R2d groups； R2a and R2b are each independently selected from the group consisting of hydrogen and C1-6alkyl； each R2c is independently selected from the group consisting of hydrogen, halogen, hydrox
